Bruno Bénédicte, Capelle Lucie, Denis Virginie, Duval Olivier, Selmouni Sorea, Villate Alban, Cabelguenne Delphine, Coiteux Valérie, Lachner-Gaubert Tiphaine, Yakoub-Agha Ibrahim, Simon Nicolas
CHU Lille, service d'hématologie pédiatrique, 59000 Lille, France.
CHU Rouen, service d'hématologie pédiatrique, 76000 Rouen, France.
Bull Cancer. 2023 Feb;110(2S):S88-S96. doi: 10.1016/j.bulcan.2022.02.004. Epub 2022 May 3.
Since patients require multiple intravenous drugs, drug incompatibilities and drug interactions are frequent during the acute phase following hematopoietic cell transplantation. The risk of drug-drug interactions is increased in patients with several comorbidities. The goal of this workshop was to learn how to mitigate the risks of drug incompatibilities and interactions when their usage is therapeutically warranted. Our focus was on proton pump inhibitors and antiemetic drugs as they are routinely used in hematopoietic transplants and frequently lead to incompatibilities and interactions with other drugs such as immunosuppressives and antimicrobials. Routine procedures in transplantation such as the choice of vascular access devices, the setting of infusion lines, the scheduling of administration of drugs and their dilution volumes can be effective armaments to mitigate the risks of drug incompatibilities and interactions. In addition, a multidisciplinary concertation between clinicians, pharmacists and nurses is a key point in the success of patient's care.
